Keep Factually independent
Whether you agree or disagree with our analysis, these conversations matter for democracy. We don't take money from political groups - even a $5 donation helps us keep it that way.
Who holds the patents for Neurocept's active compound and when were they filed?
Executive summary
Available sources do not directly state who holds patents for "Neurocept’s active compound" or when those patents were filed; the materials returned by the search instead include unrelated Neurotech/Neurotech USA patent listings, broader analyses of neurotechnology patenting, and trade/marketing pages for a supplement named Neurocept (not patent filings) [1] [2] [3]. Because the specific claim — a patent owner and filing date tied to a Neurocept active compound — is not present in the supplied reporting, I cannot name patent holders or filing dates from these sources [1] [2] [3].
1. What the returned patent records actually cover
The patent snippets in the search results mainly concern companies and filings in the neurotech / neuropharmaceutical space broadly, not a Neurocept active compound. For example, Justia shows patents assigned to Neurotech USA, Inc., including a July 15, 2025 patent on ophthalmic device methods and devices (inventors listed) [1]. Another Justia result lists a patent application (publication 20250262261) about cannabinoid compositions filed October 11, 2022 and published August 21, 2025, attributed to "Neurotech" [2]. None of these entries mention an entity named "Neurocept" or a discrete active compound called "Neurocept" [1] [2].
2. Marketing pages vs. patent records — same name, different evidence
A commercial website and a press release-style item refer to a product called Neurocept marketed as a cognitive-support supplement, describing ingredients and claims about memory, energy, and mitochondrial support [3] [4]. Those pages do not include patent assignment data or filing dates and therefore cannot be used as evidence of patent ownership. The search results also list a consumer product listing (eBay) for a similarly named supplement but again with no patent data [5] [3].
3. Broader patent landscape for neurotech and CNS compounds
Independent coverage in the results discusses the growth and ethical regulation of neurotechnology patents and shows that the field contains many patent filings spanning devices, formulations, and active molecules [6] [7]. Academic and industry analyses point out that companies commonly file primary (active ingredient) patents and later ancillary patents on formulation or delivery; these practices complicate answering “who owns what” without checking specific patent families [8] [7]. That context explains why a simple web search might return many related but not definitive records [8] [7].
4. Examples of relevant patent filings in CNS / neuroactive space
Search results include concrete patent documents for neuroactive steroids and other CNS-focused formulations (e.g., WO2016205721A1 and US10322139 concerning neuroactive steroid formulations assigned to Sage Therapeutics, and other Google Patents entries on BDNF activation and neuromodulation) — demonstrating how active CNS compounds are typically protected by patent families with explicit filing and publication dates [9] [10] [11]. Those examples illustrate where to look for claims about an active molecule: patent family entries and Google Patents / Justia records [9] [10].
5. Why the specific Neurocept patent question remains unanswered in these results
None of the supplied patent database snippets or articles name a patent that claims an “active compound” called Neurocept, nor do they provide a filing date or assignee tied to that label. Because the developer guidance requires using only the provided sources, I must report that the information you asked for is not found in current reporting supplied here [1] [2] [3]. If a Neurocept active compound is protected by patents, that ownership and filing data are not present among these results.
6. How to get a definitive answer (next steps)
To resolve this precisely, consult primary patent databases (USPTO, Espacenet, WIPO Patentscope, Google Patents, Justia) and search for patent families and assignees using variations of the product and chemical names (e.g., “Neurocept,” the active ingredient’s chemical name if known, and common assignee names). The search results here show those databases are where CNS and neurotech patents appear [1] [2] [9]. Also compare commercial trademarks and product pages (which often do not equate to patents) with official patent records to avoid conflating marketing claims with IP ownership [3].
Limitations: I used only the documents returned in your search prompt. Because none explicitly link Neurocept’s “active compound” to a patent holder or filing date, I cannot invent or infer ownership or dates beyond what these sources show [1] [2] [3].